NITAZOXANIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H9N3O5S
Molecular Weight	307.2835
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)Oc1ccccc1C(=Nc2ncc(N(=O)=O)s2)O

InChI

InChIKey=YQNQNVDNTFHQSW-UHFFFAOYSA-N

InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)

HIDE SMILES / InChI

Molecular Formula	C12H9N3O5S
Molecular Weight	307.2835
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021818lbl.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/21397502
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25762088 https://www.ncbi.nlm.nih.gov/pubmed/20404119 https://www.ncbi.nlm.nih.gov/pubmed/17888524

Tizoxanide, the primary active metabolite of the FDA approved drug nitazoxanide, an anti-infective that has been approved for the treatment of diarrhea caused by Giardia lamblia. Tizoxanide, an active metabolite of nitazoxanide in humans, is also an antiparasitic drug of the thiazolide class. It has broad-spectrum antiparasitic and broad-spectrum antiviral properties. Besides, it has being found that Tizoxanide exhibits appreciable antagonist activity for both mGluR1 and mGluR5 (IC50 = 1.8 uM and 1.2 uM, respectively).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Pyruvate:ferredoxin oxidoreductase 3 Target ID: CHEMBL2364027 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021818lbl.pdf	Inhibitor 7701
Mycobacterium tuberculosis 19 Target ID: CHEMBL360 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27156623	Inhibitor 7701
Metabotropic glutamate receptor 1 22 Target ID: CHEMBL3772 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25762088	Antagonist 2577	1.8 µM [IC50]
Metabotropic glutamate receptor 5 26 Target ID: CHEMBL3227 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25762088	Antagonist 2577	1.2 µM [IC50]
Rotavirus 2 Target ID: CHEMBL613722 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23926336	Inhibitor 7701
Giardia intestinalis 2 Target ID: CHEMBL612652 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21397502	Inhibitor 7701	0.716 µM [IC50]
Trichomonas vaginalis 11 Target ID: CHEMBL612884 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21397502	Inhibitor 7701	0.211 µM [IC50]
Staphylococcus aureus 64 Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20404119	Inhibitor 7701
Hepatitis B virus 7 Target ID: CHEMBL613497 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17888524	Inhibitor 7701	0.15 µM [EC50]
Pyruvate:ferredoxin oxidoreductase 3 Target ID: CHEMBL2364026 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021818lbl.pdf	Inhibitor 7701

Conditions

Condition	Modality	Highest Phase	Product
Diarrhea caused by Giardia lamblia or Cryptosporidium parvum 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021818lbl.pdf	Curative	Approved 7997	ALINIA Approved Use Diarrhea caused by Giardia lamblia or Cryptosporidium parvum: Alinia for Oral Suspension (patients 1 year of age and older) and Alinia Tablets (patients 12 years and older) are indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum. Alinia for Oral Suspension and Alinia Tablets have not been shown to be superior to placebo for the treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients (see CLINICAL STUDIES ). Launch Date 1.09036798E12
Rotavirus gastroenteritis 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23926336	Primary	Basic research	Unknown Approved Use Unknown
Tuberculosis 80 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27156623 https://www.ncbi.nlm.nih.gov/pubmed/22589723	Curative	Basic research	Unknown Approved Use Unknown
Trichomoniasis 16 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11751773 https://www.ncbi.nlm.nih.gov/pubmed/21397502	Curative	Basic research	Unknown Approved Use Unknown
Hepatitis B 52 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17888524	Primary	Basic research	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
9.1 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021497s001,021498s004lbl.pdf	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		TIZOXANIDE plasma	Homo sapiens population: UNKNOWN age: ADOLESCENT sex: UNKNOWN food status: FED
6.795 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22533565	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		TIZOXANIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
39.5 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021497s001,021498s004lbl.pdf	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		TIZOXANIDE plasma	Homo sapiens population: UNKNOWN age: ADOLESCENT sex: UNKNOWN food status: FED
27.23 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22533565	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		TIZOXANIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.38 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22533565	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		TIZOXANIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021497s001,021498s004lbl.pdf	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		TIZOXANIDE plasma	Homo sapiens population: UNKNOWN age: ADOLESCENT sex: UNKNOWN food status: FED

Doses

Dose	Population	Adverse events
4 mg 1 times / day steady, oral MTD Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12051573/ Page: 1	healthy, adult n = 6 Health Status: healthy Age Group: adult Sex: unknown Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/12051573/ Page: 1	Other AEs: Gastrointestinal disorders NEC... Other AEs: Gastrointestinal disorders NEC Sources: https://pubmed.ncbi.nlm.nih.gov/12051573/ Page: 1

AEs

AE	Significance	Dose	Population
Gastrointestinal disorders NEC		4 mg 1 times / day steady, oral MTD Dose: 4 mg, 1 times / day Route: oral Route: steady Dose: 4 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12051573/ Page: 1	healthy, adult n = 6 Health Status: healthy Age Group: adult Sex: unknown Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/12051573/ Page: 1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1172	inhibitor 1318	inhibitor 1421

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP 97 CYP1A2 1268 CYP2C19 1215 CYP2B6 679 CYP2E1 761 CYP3A5 66

Drug as perpetrator

Target	Modality	Activity
CYP 131	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021497s001,021498s004lbl.pdf Page: 8.0	no
CYP1A2 1406	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021818s000_ClinPharmR.pdf Page: 8.0	no
CYP2B6 845	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021818s000_ClinPharmR.pdf Page: 16.0	no
CYP2C19 1277	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021818s000_ClinPharmR.pdf Page: 8.0	no
CYP2D6 1455	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021818s000_ClinPharmR.pdf Page: 8.0	no
CYP2E1 841	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021818s000_ClinPharmR.pdf Page: 16.0	no
CYP3A5 119	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021818s000_ClinPharmR.pdf Page: 16.0	no
CYP2C9 1362	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021818s000_ClinPharmR.pdf Page: 8.0	weak [IC50 >100 uM]
CYP3A4 1462	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021818s000_ClinPharmR.pdf Page: 8.0	weak

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY531640	https://www.001chemical.com/chem/173903-47-4
AA Blocks	AA001Z6T	https://www.aablocks.com/goods/Goods/detail?id=AA001Z6T
AK Scientific, Inc. (AKSCI)	8987AA	http://www.aksci.com/item_detail.php?cat=8987AA
Aaron Chemicals	AR001ZYL	http://www.aaronchem.com/173903-47-4
Acadechem	ACDS-046361	http://www.acadechemical.com/product/121060
Achemo Scientific Limited	AC-94847	http://www.achemo.com/search/?Keyword=173903-47-4
Angel Pharmatech	AG-11627	http://www.angelpharmatech.com/173903-47-4.html
Anward	ANW-60134	http://www.anward.com/pro_result/46585
Ark Pharm	AK-60881	http://www.arkpharminc.com/products/173903-47-4.html
Ark Pharma Scientific Limited	A-0871	http://www.arkpharmtech.com/product/32822.html
Aurum Pharmatech LLC	NE62763	http://www.Aurumpharmatech.com/Product/ProductDetails/NE62763
BLD Pharm	BD208327	http://www.bldpharm.com/products/173903-47-4.html
BioChemPartner	BCP08678	http://www.biochempartner.com/173903-47-4-BCP08678
BioSynth	J-010949	https://www.biosynth.com/en/products/all-products/products/J-010949.html
CSNpharm	CSN12663	https://www.csnpharm.com/products/tizoxanide.html
Capot Chemical	20794	http://www.capotchem.com/en/20794.htm
Capot Chemical	PubChem20794	http://www.capotchem.com/en/20794.htm
Chem Scene	CS-3893	http://www.chemscene.com/173903-47-4.html
Chemspace	CSSB00015203979	https://chem-space.com/CSSB00015203979
Clearsynth	CS-T-44466	https://www.clearsynth.com/en/CST44466.html
DC Chemicals	DC8336	http://www.dcchemicals.com/product_show-Tizoxanide.html
Debye Scientific	DB-064924	http://www.debyesci.com/cas_173903-47-4.html
Finetech	FT-0675256	http://www.finetechnology-ind.com/prod/detail/pub/173903-47-4.html
J&W PharmLab	90R0384	https://www.jwpharmlab.com/home/product/90R0384
Lab Network	LN00195447	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00195447
Matrix Scientific	94509	https://www.matrixscientific.com/094509.html
MedChem Express	HY-12687	https://www.medchemexpress.com/Tizoxanide.html
Molcore	MC531640	https://www.molcore.com/product/173903-47-4
Oakwood	44549	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=38424&ExtHyperLink=1
Sinfoo Biotech	S030704	http://www.sinfoobiotech.com/product/1034102
Smolecule	S545437	http://www.smolecule.com/products/s545437
Smolecule	S775909	https://www.smolecule.com/products/s775909
Synblock Inc	SB34253	http://www.synblock.com/product/173903-47-4.html
THE BioTek	bt-285752	https://www.thebiotek.com/product/inhibitors/bt-285752
abcr GmbH	AB464410	http://www.abcr.com/shop/en/AB464410
eNovation Chemicals	D544470	https://www.enovationchem.com/ProductDetails.asp?ProductID=D544470
eNovation Chemicals	D952630	https://www.enovationchem.com/ProductDetails.asp?ProductID=D952630
eNovation Chemicals	Y0974571	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0974571
eNovation Chemicals	Y1008359	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1008359

PubMed

Title	Date	PubMed
New drugs and treatment for cryptosporidiosis.	2004 Dec	15640710
Evaluation of the in vitro effect of albendazole, metronidazole and nitazoxanide on viability and structure of Giardia lamblia cysts.	2004 Jul-Oct	15906598
Nitazoxanide: a new thiazolide antiparasitic agent.	2005 Apr 15	15791519
Treatment of cryptosporidiosis in immunocompromised hosts.	2005 Jul	16006765
Use of nitazoxanide as a new therapeutic option for persistent diarrhea: a pediatric perspective.	2005 Jul	16004666
Nitazoxanide for persistent diarrhoea in Zambian acquired immune deficiency syndrome patients: a randomized-controlled trial.	2005 Mar 15	15771762
Nitazoxanide.	2005 Nov	16340060
Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis.	2005 Oct	16234044
Molecular survival strategies of Echinococcus multilocularis in the murine host.	2006	16352460
Practical considerations of new drugs: new choices for old problems.	2006 Apr	16669748
[Development of novel antihelminthic therapies].	2006 Aug	16999038
[Therapeutic alternatives in case of failure of first-line treatment of intestinal helminthiasis in adults].	2006 Aug	16999037
Current status of anti-diarrheal and anti-secretory drugs in the management of acute childhood diarrhea.	2006 Aug	16936364
Treatment options for the eradication of intestinal protozoa.	2006 Aug	16883348
Nitazoxanide for the treatment of Clostridium difficile colitis.	2006 Aug 15	16838229
Past, present, and future therapies for Clostridium difficile-associated disease.	2006 Dec	17148650
Emerging therapies in the treatment of Clostridium difficile-associated disease.	2006 Dec	17119105
Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model.	2006 Feb	16361328
14-3-3- and II/3-10-gene expression as molecular markers to address viability and growth activity of Echinococcus multilocularis metacestodes.	2006 Jan	16393357
Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial.	2006 Jul 8	16829296
Nitazoxanide for rotavirus diarrhoea?	2006 Jul 8	16829280
An update on diagnosis, treatment, and prevention of Clostridium difficile-associated disease.	2006 Jun	16880068
Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species.	2006 Mar	16527695
Use of nitazoxanide for gastrointestinal tract infections: treatment of protozoan parasitic infection and beyond.	2006 Mar	16524544
Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections.	2006 May	16634717
Antimicrobial therapy of Clostridium difficile-associated diarrhea.	2006 Nov	17116441
Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial.	2006 Nov 15	17081163
Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients.	2006 Sep 1	16918894
Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.	2007 Apr	17337513
Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis.	2007 Apr	17335543
Characterization of Giardia lamblia WB C6 clones resistant to nitazoxanide and to metronidazole.	2007 Aug	17561498
Induction of tachyzoite egress from cells infected with the protozoan Neospora caninum by nitro- and bromo-thiazolides, a class of broad-spectrum anti-parasitic drugs.	2007 Aug	17481636
Nitazoxanide or CD3+/CD4+ lymphocytes for recovery from severe Cryptosporidium infection after allogeneic bone marrow transplant?	2007 Feb	17239134
Severe cryptosporidiosis in a seven-year-old renal transplant recipient: case report and review of the literature.	2007 Feb	17239130
Structure-activity relationships from in vitro efficacies of the thiazolide series against the intracellular apicomplexan protozoan Neospora caninum.	2007 Feb	17141783
Efficacy of nitazoxanide, tizoxanide and tizoxanide/albendazole sulphoxide combination against Taenia crassiceps cysts.	2007 Feb	17114175
Hymenolepis nana infection: symptoms and response to nitazoxanide in field conditions.	2007 Feb	16814334
Efficacy of nitazoxanide for cyclosporiasis in patients with sulfa allergy.	2007 Feb 1	17205465
Nitazoxanide versus metronidazole for Clostridium difficile-associated colitis.	2007 Jan 1	17143841
Prevention and treatment of cryptosporidiosis in immunocompromised patients.	2007 Jan 24	17253532
[New drugs against parasitic diseases].	2007 Jan 31	17432522
Clostridium difficile: recent epidemiologic findings and advances in therapy.	2007 Jul	17594209
In vitro efficacy of nitro- and bromo-thiazolyl-salicylamide compounds (thiazolides) against Besnoitia besnoiti infection in Vero cells.	2007 Jul	17306057
Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.	2007 Jul 18	17636768
Is nitazoxanide an effective treatment for patients with acquired immune deficiency syndrome-related cryptosporidiosis?	2007 Mar	17245327
Isolated gastric cryptosporidiosis in an immunocompetent patient.	2007 May	17372826
Nitazoxanide in the treatment of amoebiasis.	2007 Oct	17658567
Clostridium difficile: new therapeutic options.	2007 Oct	17644040
Failure of nitazoxanide to cure trichomoniasis in three women.	2007 Oct	17551415
Nitazoxanide in the treatment of Ascaris lumbricoides in a rural zone of Colima, Mexico.	2007 Sep	17594741

Patents

Sample Use Guides

In Vivo Use Guide

Nitazoxanide treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum: 1-3 years old patients: 5 mL of Alinia for Oral Suspension (100 mg nitazoxanide) every 12 hourswith food for 3 days; 4-11 years old patients: 10 mL of Alinia for Oral Suspension (200 mg nitazoxanide) every 12 hours with food for 3 days; ≥12 years old patients: 1 Alinia Tablet (500 mg nitazoxanide) every 12 hours with food or 25 mL of Alinia for Oral Suspension (500 mg nitazoxanide) every 12 hours with food for 3 days

Route of Administration: Oral

In Vitro Use Guide

Nitazoxanide and its metabolites tizoxanide and tizoxanide glucuronide were inhibitory for up to 46 h when added after Cryptosporidium parvum sporozoite invasion in differentiated human enterocytic HCT-8 cells (MIC50 1.2, 22.6 and 2.2 mg/L, respectively).

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:52:46 UTC 2021` Edited by `admin` on `Fri Jun 25 21:52:46 UTC 2021`
Record UNII	SOA12P041N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NITAZOXANIDE

Official Name

English

NITAZOXANIDE [GREEN BOOK]

Common Name

English

ALINIA

Brand Name

English

NITAZOXANIDE [VANDF]

Common Name

English

NITAZOXANIDE [INN]

Common Name

English

NITAZOXANIDE [ORANGE BOOK]

Common Name

English

NSC-760057

Code

English

NITAZOXANIDE [MI]

Common Name

English

NITAZOXANIDE [USP-RS]

Common Name

English

PH 5776

Code

English

N-(5-NITROTHIAZOL-2-YL)SALICYLAMIDE ACETATE ESTER

Common Name

English

NITAZOXANIDE [WHO-DD]

Common Name

English

NITAZOXANIDE [USAN]

Common Name

English

NSC-697855

Code

English

BENZAMIDE, 2-(ACETYLOXY)-N-(5-NITRO-2-THIAZOLYL)-

Systematic Name

English

PH-5776

Code

English

NITAZOXANIDE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C277